> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Gilead Sciences Gets Priority Voucher for Veklury
- URL: https://www.fdaweb.com/gilead-sciences-gets-priority-voucher-for-veklury/
- Published: 2022-04-29T12:00:00.000Z
- Updated: 2026-09-14T17:42:43.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151708

*Federal Register* notice: FDA has issued a priority review voucher to Gilead Sciences under the agency’s material threat medical countermeasure program. FDA determined that recently approved Veklury (remdesivir) meets the criteria for such a voucher. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-04-29/pdf/2022-09233.pdf?ref=fdaweb.com).